VEGFA and neoplasm: Anti-vascular endothelial growth factor-targeted therapies can induce hypoxia and promote an immunosuppressive tumor microenvironment by upregulating immune checkpoint molecules [15, 16]; thus, the combination of anti-angiogenic agents with immunotherapy is particularly attractive.